Unknown

Dataset Information

0

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.


ABSTRACT: The triple negative basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease. Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined. Thus, our work focused on the analysis of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concentration. Western blot analyses showed a clear coexpression of P-gp and BCRP in SUM1315 cells. A low cytotoxic Olaparib treatment clearly led to an increased expression of both BCRP and P-gp in these cells. Indeed, after 1.5 h of treatment, BCRP expression was increased with a 1.8 fold increase rate. Then, P-gp took over from 3 h to 15 h with an average increase rate of 1.8 fold, and finally returned to control value at 24 h. HPLC-UV analyses showed that, in the same treatment conditions, the intracellular Olaparib concentration increased from 1 h to 3 h and remained relatively stable until 24 h. Results suggest that the resistance mechanism induced by Olaparib in TNBL SUM1315 cell line may be overpassed if a cytotoxic and stable intracellular level of the drug can be maintained.

SUBMITTER: Dufour R 

PROVIDER: S-EPMC4522660 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour Robin R   Daumar Pierre P   Mounetou Emmanuelle E   Aubel Corinne C   Kwiatkowski Fabrice F   Abrial Catherine C   Vatoux Catherine C   Penault-Llorca Frédérique F   Bamdad Mahchid M  

Scientific reports 20150803


The triple negative basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease. Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined. Thus, our work focused on the analysis of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concentration. Western blot  ...[more]

Similar Datasets

2021-07-22 | GSE165914 | GEO
2022-04-21 | GSE149621 | GEO
| S-EPMC3813570 | biostudies-literature
| S-EPMC7102473 | biostudies-literature
| S-EPMC3579595 | biostudies-literature
| S-EPMC11136660 | biostudies-literature
| S-ECPF-GEOD-41119 | biostudies-other
| S-EPMC3362790 | biostudies-literature
| S-EPMC3775628 | biostudies-literature
| S-EPMC7921931 | biostudies-literature